Journal of Chemotherapy 2009-04-01

The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.

G Braccini, F Festini, V Boni, A S Neri, V Galici, S Campana, L Zavataro, F Trevisan, C Braggion, G Taccetti

Index: J. Chemother. 21(2) , 188-92, (2009)

Full Text: HTML

Abstract

The aim of cystic fibrosis (CF) care is to improve both the life expectancy and quality of life of patients. However, rising costs and limited resources of health services must be taken into account. There are many different antibiotic strategies for therapy of Pseudomonas aeruginosa infection in CF patients. In this 5-year retrospective study we found that the cost of treatment of initial infection is considerably lower than the cost of treating chronic P. aeruginosa infections. The percentage distribution of costs of antibiotic treatment in relationship to the administration route was considerably different between outpatients and inpatients. We observed an increase in antibiotic costs with the age of the patient and the decrease in FEV(1)values. The implementation of early eradication treatment, in addition to decreasing the prevalence of patients chronically infected by P. aeruginosa, might also bring about a notable decrease in costs.

Related Compounds

  • Ticarcillin

Related Articles:

Methyl gallate from Galla rhois successfully controls clinical isolates of Salmonella infection in both in vitro and in vivo systems.

2014-01-01

[PLoS ONE 9(7) , e102697, (2014)]

Genetic characterization of oropharyngeal trichomonad isolates from wild birds indicates that genotype is associated with host species, diet and presence of pathognomonic lesions.

2014-01-01

[Avian Pathol. 43(6) , 535-46, (2014)]

Characterization of Acinetobacter baumannii clinical isolates carrying bla(OXA-23) carbapenemase and 16S rRNA methylase armA genes in Yemen.

2014-12-01

[Microb. Drug Resist. 20(6) , 604-9, (2014)]

Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.

2012-01-01

[Cochrane Database Syst. Rev. 12 , CD008319, (2012)]

Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.

2009-08-01

[Antimicrob. Agents Chemother. 53 , 3357-64, (2009)]

More Articles...